Casdin Capital and Redmile Group led a $125m funding round in AbSci, a synthetic biology company, with participation from Fidelity Management and Research Company, D1 Capital Partners, Perceptive Advisors, aMoon Edge, Irving Investors, and ArrowMark Partners. "We are thrilled to have such a well-respected group of life sciences investors who share our vision of transforming the way drugs are created. As we unlock access to novel biologies and therapeutic modalities, and work with our partners to create exciting new medicines, we are continuing to innovate and expand the scope of what we can accomplish and the impact we can have to improve human health," Sean McClain, AbSci Founder and CEO.